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Abstract
Background: Although fibroblast growth factor (Fgf) signalling plays crucial roles in several developing
and mature tissues, little information is currently available on expression of Fgf2 during early choroid
plexus development and whether Fgf2 directly affects the behaviour of the choroid plexus epithelium
(CPe). The purpose of this study was to investigate expression of Fgf2 in rodent and human developing
CPe and possible function of Fgf2, using in vitro models. The application of Fgf2 to brain in vivo can affect
the whole tissue, making it difficult to assess specific responses of the CPe.
Methods: Expression of Fgf2 was studied by immunohistochemistry in rodent and human embryonic
choroid plexus. Effects of Fgf2 on growth, secretion, aggregation and gene expression was investigated
using rodent CPe vesicles, a three-dimensional polarized culture model that closely mimics CPe properties
in vivo, and rodent CPe monolayer cultures.
Results:  Fgf2 was present early in development of the choroid plexus both in mouse and human,
suggesting the importance of this ligand in Fgf signalling in the developing choroid plexus. Parallel analysis
of Fgf2 expression and cell proliferation during CP development suggests that Fgf2 is not involved in CPe
proliferation in vivo. Consistent with this observation is the failure of Fgf2 to increase proliferation in the
tri-dimensional vesicle culture model. The CPe however, can respond to Fgf2 treatment, as the diameter
of CPe vesicles is significantly increased by treatment with this growth factor. We show that this is due to
an increase in cell aggregation during vesicle formation rather than increased secretion into the vesicle
lumen. Finally, Fgf2 regulates expression of the CPe-associated transcription factors, Foxj1 and E2f5,
whereas transthyretin, a marker of secretory activity, is not affected by Fgf2 treatment.
Conclusion: Fgf2 expression early in the development of both human and rodent choroid plexus, and its
ability to modulate behaviour and gene expression in CPe, supports the view that Fgf signalling plays a role
in the maintenance of integrity and function of this specialized epithelium, and that this role is conserved
between rodents and humans.
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Background
The choroid plexus epithelium (CPe) is a specialized neu-
roepithelium that is involved in secretion of cerebrospinal
fluid (CSF) into the cerebral ventricles and in maintaining
the homeostasis of the brain during development and
throughout life [1-3]. Most CSF is secreted by the CPe and
is re-absorbed mainly at the site of the arachnoid villi.
Knockout of genes expressed in the CPe, such as E2f5, a
member of a family (E2f1–E2f6) of transcriptional regula-
tors, FoxJ1, a member of the forkhead-box (Fox)/winged
helix gene family, and p73, have been associated with
hydrocephalus [4-6]. The mechanisms leading to the
apparently non-obstructive hydrocephalus in these
mutants appear to differ and have yet to be fully eluci-
dated. These genes are expressed early during CPe devel-
opment in rodent and humans [6-11] and Foxj1 has been
reported to be down-regulated by Fgf2 (fibroblast growth
factor 2) in neural cells [12].
Some biogenic amines, neuropeptides and hormones also
have the ability to modulate the function of the CPe,
including its secretory activity [13-17], but the effect of
growth factors on its cellular function has not been well
studied, especially in the embryonic CPe. Fgf2 has been
implicated in the regulation of cell survival and apoptosis,
adhesion, motility, and differentiation [18], and in the
brain, among other effects, in the control of neural stem
cell proliferation both during development and in the
adult following intraventricular administration. It has
also been suggested that Fgf treatment can stimulate neu-
rogenesis and aid repair following brain injury [19-21].
Injection of Fgf2 into the ventricles of the brain, however,
has been reported to induce hydrocephalus [22-24]. This
could be a hindrance in the development of Fgf-based
treatments [25], as the mechanisms underlying the effect
of Fgf2 on CSF accumulation remain unclear. Given that
Fgf can affect several cell types in the brain, induction of
hydrocephalus following Fgf administration might not be
due to a direct effect of Fgf on the CPe. On the other hand,
Fgf2 might directly affect CSF secretion or reabsorption
[23] or even CSF circulation. For example, defects in cilio-
genesis, as reported in the FoxJ1 knock-out mouse, can
affect CSF dynamics in the ventricles and result in hydro-
cephalus [5].
As members of the fibroblast growth factor receptor fam-
ily (FgfR 1–4) are expressed in the CPe and are differen-
tially regulated during development [26], it is likely that
Fgf signalling can directly affect at least some aspects of
CPe cell behaviour. While in vitro models cannot repro-
duce the complexity of the responses leading to the hydro-
cephalic phenotype in vivo, they can allow the direct
effects of Fgf on CPe cells to be tested.
At least one FgfR ligand, Fgf2, is known to be expressed in
the adult and foetal CPe [27-29], but its expression during
early development has not been investigated either in
rodents or humans. We have therefore assessed Fgf2 pat-
tern of expression during mouse and human CP develop-
ment in relation to proliferation. Having found that Fgf2
protein is expressed both in human and mouse embry-
onic choroid plexus, we have used embryonic CP cells cul-
tured in Matrigel to investigate putative roles of Fgf2 on
CPe behaviour. In this tri-dimensional matrix, embryonic
CP cells form fluid-filled spherical structures called vesi-
cles, and we have recently shown that their growth
depends on secretion within the lumen [30,31]. The CPe
phenotype and the behaviour of the cells in this culture
system appear to be very similar to that in vivo, represent-
ing a valuable model to assess the effect of growth factors
on cell-cell adhesion and cell migration as well as fluid
secretion and solute transport [30]. This is further sup-
ported by this study, as we show that Fgf2 does not affect
CPe proliferation in vitro in a tri-dimensional environ-
ment, consistent with the significant Fgf2 expression and
limited proliferation observed in the choroid plexus in
vivo. We also show that whereas Fgf2 treatment in vitro
affects CPe vesicle formation in a dose-dependent fash-
ion, it does not alter its secretory activity. Fgf2, however,
can regulate expression of the CPe-associated transcrip-
tion factors E2f5 and FoxJ1. Altogether this study suggests
that Fgf signalling plays a role in CPe development and
possibly in its integrity and homeostasis.
Methods
Tissue collection and reagents
Choroid plexus for cultures, and brains to be fixed in 4%
paraformaldehyde and paraffin embedded for immuno-
histochemistry were dissected from out-bred CD-1 albino
mice supplied by Charles River Mouse Farms (Kent, UK)
and housed under Home Office regulations. The morning
of detection of a vaginal plug was designated as embry-
onic day 0.5 (E0.5). Mice were killed by cervical disloca-
tion according to Home Office regulations at the times
indicated in the results section and embryos removed for
immunohistochemical analysis or CPe culture prepara-
tion as described below. Paraffin sections from human
embryos at 8 weeks of gestation obtained under ethical
approval were provided by the Wellcome/MRC-funded
Human Developmental Biology Resource. Unless other-
wise specified, reagents used were from Sigma-Aldrich,
UK.
Choroid plexus cell cultures
The fourth ventricle CP from E12.5 mice was dissected
and CP cells isolated and cultured as previously described
[30,31]. Cells were grown in HEPES-buffered Dulbecco's
modified essential medium (H-DMEM, Gibco-BRL, Pais-
ley, UK) supplemented with 10% foetal calf serum (FCS)Cerebrospinal Fluid Research 2008, 5:20 http://www.cerebrospinalfluidresearch.com/content/5/1/20
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and penicillin-streptomycin (Gibco-BRL) either as mon-
olayers on laminin (Sigma, UK) or seeded in Matrigel
(Becton Dickenson, distributed by Stratech Scientific Ltd,
Dudley, UK) to allow vesicle formation. In vesicle culture
experiments 1–2 × 105  CPe cells were plated on to
Matrigel in cloning cylinders of 8 mm diameter and fed
every 2–3 days with the culture medium described above.
The TRCSFB-2 cell line was established from CPe cells iso-
lated from a transgenic rat harboring the temperature-sen-
sitive simian virus 40 (ts SV 40) large T-antigen gene [32].
Cells were grown in DMEM (Gibco-BRL) supplemented
with 10% FCS and penicillin-streptomycin on collagen I
(Vitrogen, Cohesion Technologies, Inc. CA, USA) at 33°C
[32]. Before carrying out RNA expression studies, TRCSFB-
2 cells were cultured for 24 h at 37°C.
Cell analysis and treatments
CPe behaviour was monitored by regular observation
under an inverted microscope (IM45 Zeiss) and by time-
lapse photography for up to 4 consecutive days using
Openlab software (Improvision, UK). For Fgf2 treatment,
Fgf2 (R&D Systems, Oxford, UK) at the desired concentra-
tion was added to the culture medium either at the time
of plating CPe cells or later as specified in the Results. To
study the effect of Fgf2 on vesicle recovery after inhibition
of secretion and collapse, cultures were treated for 48 h
either with a combination of 100 μM acetazolamide and
5 mM ouabain or with the vehicle alone (DMSO con-
trols).
Proliferation analysis and immunohistochemistry
Fgf2 was detected by an anti-Fgf2 mouse monoclonal
antibody (Transduction Laboratories, Lexington, UK,
1:100 dilution). Cell proliferation was detected by: anti-
bromo-deoxyuridine (BrdU) rat monoclonal antibody to
detect cells in S phase that had incorporated BrdU
(Oxford Biotechnology, Oxford, UK, 1:100); anti-phos-
phorylated-histone 3 (p-H3) rabbit antibody to detect
cells in M phase (Upstate Biotechnology, Buckingham,
UK; 1:100 or 1:500 dilution, see below); a mouse mono-
clonal antibody to PCNA, an auxiliary factor for DNA
polymerase delta, to detect cells in G1-S phase (clone
PC10, Santa Cruz Biotechnology, Inc., CA, USA, 1:100).
The secondary antibodies used, fluorescein-conjugated
goat anti-rabbit (1:50 dilution), and peroxidase-conju-
gated goat anti-rabbit, goat anti-mouse and goat anti-rat
immunoglobulins (1:100 dilution), were all from DAKO
(Bucks, UK). Hoechst dye H33258 (1:500 dilution of a
1.2 mg/ml stock) was used to counter-stain nuclei.
Mitotic cells in CPe vesicles and aggregates were detected
using the anti-p-H3 antibody. Cells grown in Matrigel
inside cloning cylinders placed onto glass coverslips were
fixed in 4% paraformaldehyde (PFA) for 10 min. Non-
specific binding sites were blocked with 1% goat serum in
PBS for 40 min. CPe vesicles/aggregates were incubated
overnight at 4°C with the anti-p-H3 antibody, thoroughly
washed and incubated with fluorescein-conjugated goat
anti-rabbit for 30 min. Nuclei were counterstained for 15
min with Hoechst dye.
The anti-PCNA monoclonal antibody was used to stain
primary CPe cells fixed for 10 min in 4% PFA. Bound anti-
body was detected using a fluorescein-conjugated goat
anti-mouse antibody and nuclei counterstained with
Hoechst dye. Paraffin sections were stained either with the
anti-Fgf2 mouse monoclonal antibody or with the anti-p-
H3 rabbit antibody (1:500 dilution) essentially as previ-
ously described [7,26].
Tissues and cells were viewed under a Zeiss Axioplan
microscope and digitally scanned using a Hamamatsu
digital camera (C4742-95, Hamamatsu Photonics KK,
Japan) into Openlab software (Improvision Ltd, Coven-
try, UK).
RT-PCR
TRCSFB-2 cells were trypsinised and the pellet stored in 1
ml TRI-Reagent at -20°C until RNA extraction following
the manufacturer's protocol. cDNA was synthesised from
1 μg of RNA using M-MLV reverse transcriptase and ran-
dom hexamers according to the manufacturer's instruc-
tions (Promega, Southampton, UK). The PCR step was
performed using Taq polymerase at an annealing temper-
ature of 57°C with specific primer pairs for each gene,
which were designed to span intron-exon boundaries to
exclude genomic DNA contaminations. The linearity
range of amplification for each set of primers was evalu-
ated and the number of cycles selected accordingly. The
primers (Genosys, Cambridge, UK) used and number of
cycles and product size (in brackets) are: Gapdh (20, 491
bp) 5' TTCCAGTATGACTCCACTCACG 3', 5' GGATGCAG-
GGATGATGTTCT 3'; E2f5 (25, 227 bp) 5' TGTGGCTA-
CAGCAAAGCATC 3', 5' GGCCCTGAGTGACTCTTCAG 3';
FoxJ1 (25, 205 bp) 5' TACTGCTGACCCAGGAGGAG 3', 5'
GGTAGCAGGGCAGTTGATGT 3',  TTR  (30, 505 bp) 5'
CAGATCCACAAGCTCCTGAC 3',  5' CTGCTTTGGCAA-
GATCCTGC 3'; p73 (30, 253 bp) 5' AGAGTGTGGTTGT-
GCCGTATG 3', 5' TCCCGGTAATGGTCTTCATC 3'. PCR
products were visualized on a 1.5% agarose gel containing
ethidium bromide under ultraviolet light and imaged by
using a Gel imaging system and Alphaease 3.3 software
(GRI Ltd, Braintree, UK).
Measurements and statistical analysis
The diameter of each vesicle was measured using an eye-
piece graticule at ×20 magnification. Measurements were
taken to within the nearest quarter graduation on the eye-
piece. Each vesicle could be identified easily by recordingCerebrospinal Fluid Research 2008, 5:20 http://www.cerebrospinalfluidresearch.com/content/5/1/20
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the co-ordinates on a finely graduated x-y stage and was
measured at 2-day intervals at approximately the same
time of day on days 4, 6, 8, and 10. The diameters were
recorded 'blind' to treatment group.
The number and size of aggregates and vesicles was meas-
ured using the Openlab 3.1.5 software. The size of aggre-
gate and vesicles was estimated by measuring the surface
area in μm2 of their focal equatorial plane. The measure-
ments were automatically recorded by the Openlab 3.1.5
programme, stored in Microsoft Excel and later trans-
ferred to SPSS Statistics 11.5 (SPSS Inc.) for statistical
analysis. Aggregates and vesicles were measured in the
same fields at different days. Four fields of view were
taken on each measurement day. Cell motility was
assessed following time-lapse photography by measuring
the distance travelled by a cell using the Openlab 3.1.5
software.
Data are expressed as means ± standard error of the mean
(mean ± SEM). Parametric and non-parametric tests as
appropriate were used to compare treatment groups at dif-
ferent time points. Regression analysis was used to quan-
tify the effects of treatments over time when different
vesicles were assessed on each day. Multilevel modelling
was used to model the serial changes in individual vesicles
over time [33]. Results are presented with 95% confidence
intervals.
Results
Expression of Fgf2 and the mitotic marker, p-H3 in 
developing CPe
Previously, expression of Fgf2 in the CPe has not been
studied at early developmental stages, nor across species.
Therefore, this study investigated whether Fgf2 is present
in the early embryonic mouse and human CP by immu-
nohistochemistry. In the E12.5 mouse IVth ventricle CP,
Fgf2 protein was strongly expressed in the epithelium and
more weakly in the mesenchyme (Fig. 1A–B), and its
expression was maintained at E16.5 (not shown). High
levels of Fgf2 protein were also detected in both IVth and
lateral ventricle CPe of human embryos at 8 weeks of ges-
tation (Fig. 1C–E). To establish whether Fgf2 is expressed
in dividing CP cells, we analysed E12.5 mouse IV and lat-
eral ventricle CPe using the mitotic marker, p-H3 (phos-
phorylated histone 3). Very rarely p-H3 staining was
observed in IVth and lateral ventricle CPe, whereas cells of
the ventricular zone were frequently labelled (Fig. 1F–G).
Some p-H3 positive cells were observed in the CP stalk of
the IV ventricle (Fig. 1G). The noticeable difference in the
expression patterns of Fgf2 and p-H3 suggests that the
main role of Fgf2 during CPe development is not the con-
trol of CP cell proliferation.
Effect of FGF2 on CPe proliferation and vesicle diameter
As the CPe expresses Fgf2 and FgfRs, and at least FgfR2 is
detected in CPe vesicles ([26] and unpublished observa-
tion), we further investigated the effect of Fgf2 on cell pro-
liferation in primary CPe cells grown as monolayers and
in CPe vesicles. We first studied the effect of different
doses of Fgf2 on the proliferation of TRCSFB-2 cells (data
not shown). Fgf2 significantly increased anti BrdU incor-
poration at 1 and 10 ng/ml compared to controls (p <
0.001). However, with increasing dose of Fgf2 the stimu-
lation of cell proliferation declined and at the highest Fgf2
concentration tested (100 ng/ml) no difference in
TRCSFB-2 proliferation was observed compared to
untreated controls. Similarly, 10 ng/ml Fgf2 significantly
increased cell proliferation in primary embryonic CPe
cells grown as monolayers (p < 0.0001) (data not shown).
Unlike in CPe monolayers, very few cells in control vesi-
cles were mitotic (Fig. 2A–B), and the effect of 10 ng/ml
Fgf2 on p-H3 expression was not significant either in 1
day cultures (not shown) or in 4 day vesicle cultures (Fig.
2C). Analysis of time lapse photography over 2 to 4 days,
either at the time of plating or once vesicles had formed,
did not provide any evidence of significant cell prolifera-
tion in Matrigel either in the presence or absence of Fgf2.
Nonetheless, larger vesicles were observed in Fgf2-treated
cultures than in controls (Fig. 3A). To further investigate
Fgf2 effects on vesicle size, CPe cells plated in Matrigel
were treated with 0.75, 7.5 or 75 ng/ml Fgf2 from the time
of plating, and their diameter monitored over 8 days (Fig.
3A–B). By day 4 all Fgf2-treated vesicles were significantly
larger than controls (Student's t-test p < 0.001 for every
dose), and this effect was already significant at 0.75 ng/
ml, the lowest concentration used (Fig. 3B).
Altogether these results demonstrate that while Fgf2
increases vesicle diameter, this is not due to increased pro-
liferative activity of CPe cells. They also show that the
behaviour of CPe cells in response to Fgf2 depends on the
culture environment, given the difference in proliferative
effect in monolayer and 3-dimensional (3D) cultures.
Effect of Fgf2 on CPe vesicle secretion
Analysis of vesicle growth rate showed that the average
rate of increase in diameter assessed between 4 and 10
days in culture was the same for control and Fgf2-treated
CPe (Fig. 3B). This suggests that Fgf2 does not increase
fluid secretion into the lumen, as it has been shown that
vesicle growth rate is mainly due to secretion [30]. In
addition, when Fgf2 was added to the cultures at 6 days
(Fig. 3C), no significant difference in cell diameter
between treated and untreated vesicles was observed at 10
days in culture.
To further confirm that Fgf2 does not principally affect
fluid secretion, we studied its effects on vesicle recoveryCerebrospinal Fluid Research 2008, 5:20 http://www.cerebrospinalfluidresearch.com/content/5/1/20
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after inducing them to collapse with secretion inhibitors.
Vesicles were cultured for eight days, either with or with-
out 10 ng/ml Fgf2, and then treated for two days with 5
mM ouabain and 100 μM acetazolamide. The effect of
Fgf2 on the recovery in size of collapsed vesicles was then
assessed by measuring their area daily over eight days (Fig
4). Since the original vesicles were of variable size, the
recovery of each vesicle was expressed as percentage of its
area before addition of ouabain and acetazolamide (%
recovery). The recovery rates of the vesicles were com-
pared between the two groups using a multilevel model
(which accounted for the within vesicle correlation of
repeat measurements). The average percentage increase in
control vesicle size at each day was 1.19 times higher
(95% confidence interval: 1.17, 1.20) than the previous
day (p < 0.05). Fgf2-treated vesicles recovered slightly less
rapidly than non-treated vesicles, but the difference
between control and Fgf2 treatment groups was not signif-
icant. These results suggest that fluid secretion rate is not
altered by Fgf2 treatment, and that the observed increase
in vesicle size must be induced through different mecha-
nisms at early stages of vesicle formation.
Effect of Fgf2 on CPe vesicle formation
Having established that Fgf2 treatment does not affect ves-
icle size by increasing proliferation or secretion and that
its major effect on vesicle size occurs prior to day 4, we
investigated the effects of Fgf2 on CPe behaviour at early
stages of vesicle formation (Fig 5). To this purpose we
treated CPe with 10 ng/ml Fgf2, starting the treatment one
day after plating on to Matrigel. This allowed us to check
that the cultures were at a similar density before addition
of the growth factor, and to control for possible variability
between experiments carried out from different prepara-
tions. The aggregates in Fgf2-treated cultures appeared
already to be larger than controls after one day of treat-
ment (2 days in culture), fusing with each other much
more frequently (Fig 5A–B). After three to four days the
aggregates became hollow and formed vesicles that were
larger than those in control cultures. As shown by time-
Expression of Fgf2 and p-H3 in the mouse and human CPe Figure 1 (see previous page)
Expression of Fgf2 and p-H3 in the mouse and human CPe. (A) IV ventricle (IV) choroid plexus epithelium (CPe) in a 
sagittal section of E12.5 mouse embryo brain; positive cytoplasmic staining for Fgf2 protein is observed in the CPe and less 
strongly in the CP mesenchyme (CPm). (B) Negative control for (A). (C) Human IV ventricle CPe at 8 weeks of gestation: 
strong Fgf2 labelling is present in the CPe. (D) Human lateral ventricle CPe at 8 weeks of gestation; Fgf2 staining is mainly cyto-
plasmic. (E) Negative control for (D). (F) P-H3 staining of coronal section of E12.5 mouse embryo whole brain, including the 
choroid plexuses of the lateral ventricles. Neuroepithelial cells of the ventricular zone are frequently labelled with p-H3 anti-
body whereas p-H3 labelling in the CPs is rare. (G) Black arrow indicates p-H3 labelled cells in the IV ventricle CP stalk; red 
arrow indicates a p-H3 labelled cell in the CPm. Scale bars are 50 μm in A-B; 15 μm in C-D; 500 μm in F and 200 μm in G. CP 
= choroid plexus, CPe = choroid plexus epithelium, CPm = choroid plexus mesenchyme, L = lateral ventricle, N = neuroepi-
thelium, VZ = ventricular zone, III = third ventricle, IV = fourth ventricle.
Effect of Fgf2 on cell proliferation in CPe vesicles Figure 2
Effect of Fgf2 on cell proliferation in CPe vesicles. (A) Day 4 vesicles were stained for p-H3 and nuclei counterstained 
with Hoechst dye; the arrowhead points to a p-H3 stained cell. (B) Same field of view with Hoechst stain only. Scale bars: 25 
μm. (C) Plot of the number of p-H3 labelled cells in day 4 vesicles either untreated or treated with 10 ng/ml Fgf2 against vesicle 
total cell number. Data are means ± SEM.Cerebrospinal Fluid Research 2008, 5:20 http://www.cerebrospinalfluidresearch.com/content/5/1/20
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Effect of Fgf2 on CPe vesicle size and growth Figure 3
Effect of Fgf2 on CPe vesicle size and growth. Choroid plexus epithelial cells were cultured in Matrigel either in the pres-
ence or absence of Fgf2. (A) Micrographs of two vesicles, one control (upper panel) and one Fgf2-treated (7.5 ng/ml) taken at 
different times in culture (day 4, day 6 and day 8). (B) Graph showing the mean diameters of untreated vesicles (controls, n = 
232) and vesicles treated with 0.75 (n = 63), 7.5 (n = 96) or 75 (n = 54) ng/ml Fgf2 measured on days 4, 6, 8 and 10. At all Fgf2 
concentrations the vesicle diameter is significantly higher than in controls (p < 0.001). (C) Graph showing the average vesicle 
diameters of control vesicles (n = 96) and vesicles treated with 10 ng/ml Fgf2 from day 6 in culture (n = 110). The results were 
not significant. Data are means ± SEM.
BCerebrospinal Fluid Research 2008, 5:20 http://www.cerebrospinalfluidresearch.com/content/5/1/20
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lapse photography, both treated and untreated vesicles
were highly pulsatile (Additional files 1 and 2).
In order to quantify the effect of 10 ng/ml Fgf2, we meas-
ured the mid-plane area of CPe aggregates and vesicles in
four separate cultures (Fig 5C). Regression analysis
revealed that for every day of growth, Fgf2-treated aggre-
gates and vesicles increased in size by an additional
492.03 μm2 (SEM: 35.72) per day compared to control
cultures, and that this effect was highly significant (p <
0.01). We quantified the number of aggregates forming in
control and treated cultures, and found that their number
was significantly lower in Fgf2-treated cultures than in
controls both at one day (two days after plating) and 3
days (4 days after plating) treatment (Fig 5D), as expected
given the greater number of cells recruited into each vesi-
cle.
No obvious change in cell motility was observed when
cells were treated with 10 ng/ml Fgf2 at the time of plat-
ing. Cell migration was further assessed by measuring the
average speed of individual cells in control and 100 ng/ml
Fgf2-treated cultures, to assess whether a change in motil-
ity might be more obvious at this higher dose that induces
formation of larger vesicles. The speed of cell migration
was computed by taking the total distance a cell migrated
before incorporation into an aggregate over the amount of
time taken to do so. In control cells the average speed was
20.29 ± 4.84 μm/h, and in Fgf2-treated cells the average
speed was 20.48 ± 1.45 μm/h. The difference in cell motil-
ity was not significant. This suggests that changes in cell-
cell adhesion, rather than cell motility, are likely to be
responsible for the formation of bigger aggregates and
consequently larger vesicles in Fgf2-treated cultures.
Fgf2 regulation of genes associated with CPe function
In order to gain further insight into the possible function
of Fgf2 we investigated its effects on the expression of
E2f5, FoxJ1, p73 and transthyretin (TTR), a protein syn-
thesized and secreted by the CPe. As the TRCSFB-2 cells
appeared to behave in a similar fashion to primary mouse
CPe monolayers when treated with Fgf2 and a large
number of these cells can be easily grown, the effect of dif-
ferent concentrations of Fgf2 (1 ng/ml, not shown, 10 ng/
ml and 100 ng/ml) on gene expression was assessed using
semi-quantitative RT-PCR in TRCSFB-2 cells (Fig 6). A
consistent reduction (p < 0.05) in E2f5 and FoxJ1 tran-
scripts was induced by Fgf2 at the highest concentration
Effect of Fgf2 on recovery of collapsed vesicles Figure 4
Effect of Fgf2 on recovery of collapsed vesicles. Graph showing the recovery of collapsed CPe vesicles in response to 10 
ng/ml Fgf2 expressed as percentage of their size prior to collapse treatment with acetazolamide and ouabain (n = 110 per 
group). The extent of recovery between control and Fgf2-treated vesicles was not significantly different. Data are means ± 
SEM.Cerebrospinal Fluid Research 2008, 5:20 http://www.cerebrospinalfluidresearch.com/content/5/1/20
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Figure 5 (see legend on next page)Cerebrospinal Fluid Research 2008, 5:20 http://www.cerebrospinalfluidresearch.com/content/5/1/20
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Fgf2 effect on early CPe vesicle formation Figure 5 (see previous page)
Fgf2 effect on early CPe vesicle formation. (A-B) Early formation of vesicles in the presence of 0 ng/ml (A) or 10 ng/ml 
(B) Fgf2 monitored in the same field of view at one, two and four days after plating in Matrigel. Note that on day 1, just before 
adding Fgf2 to the cells, CPe aggregates in (A) and (B) are similar in size. On day 2, Fgf2-treated CPe cells have formed bigger 
aggregates that are fewer in number compared to non-treated cells. On day 4, vesicles in the Fgf2-treated culture are larger 
than in control culture, but fewer in number. (C) Graph showing the average size of aggregates and vesicles in cultures treated 
without (control) or with 10 ng/ml Fgf2 at different times after seeding according to a multiple linear regression analysis. The 
fitted lines show that Fgf2-treated aggregates and vesicles become bigger in size over time. The average size difference between 
control and Fgf2 treated cultures is 462.5 μm2 (SEM: 87.25 μm2), and Fgf2-treated aggregates increase every day on average by 
492.03 μm2 (compared to control aggregates. (D) Bar chart showing the mean number of aggregates and vesicles in cultures 
treated without or with 10 ng/ml Fgf2. At day 2 and day 4 after seeding, the number of aggregates and vesicles is significantly 
lower in Fgf2-treated cultures compared to controls (p < 0.05), whereas before the addition of Fgf2 on day 1, the difference is 
not significant. Data are means ± SEM.
Effect of Fgf2 on the expression of genes associated with CPe development and function in TRCSFB-2 cells Figure 6
Effect of Fgf2 on the expression of genes associated with CPe development and function in TRCSFB-2 cells. The 
bar charts show the average level of mRNA expression for A: E2f5 (n ≥ 9), B: FoxJ1 (n ≥ 12), C: p73 (n ≥ 7) and D: TTR (n ≥ 11) 
in response to increasing Fgf2 concentrations (0 ng/ml, 10 ng/ml, 100 ng/ml). Expression of each gene was assessed by RT-PCR 
and normalised against expression of the housekeeping gene, GAPDH. Both E2f5 and FoxJ1 transcripts are significantly reduced 
by treatment with 100 ng/ml (p < 0.05). Data are means ± SEM.Cerebrospinal Fluid Research 2008, 5:20 http://www.cerebrospinalfluidresearch.com/content/5/1/20
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tested, 100 ng/ml, (Fig 6A–B), but TTR and p73 expression
was not significantly affected at any Fgf2 concentration
(Fig 6C–D). These results suggest that Fgf2 may play a role
in modulating CPe function.
Discussion
Fgf2 expression is an early event in CPe development
It was shown here that Fgf2 is expressed not only in
mature CPe as previously reported [27,28], but also at
early embryonic stages, and that such expression is con-
served between mouse and human. As FgfRs are also
expressed in the developing choroid plexus in both spe-
cies [26,34], it is likely that Fgf2 can behave in an auto-
crine fashion in vivo, consistent with its ability to respond
to Fgf2 in vitro demonstrated in this study.
Analysis of Fgf2 expression, cell division during develop-
ment, and the effect of Fgf2 on CP cells cultured in
Matrigel suggest that this growth factor does not play a key
role in CPe growth. Whilst the concentrations of the
growth factor used here (mainly 10 ng/ml) and in many
in vitro studies may seem high in comparison to that in
CSF in vivo [35], it is the concentration of Fgf2 at the cell
surface which is critical [12,36-38]. As discussed above,
autocrine and paracrine Fgf signalling is likely to occur in
the CPe, and Fgf2 availability is regulated by the extracel-
lular matrix. Although in our 3D culture system the bioa-
vailability of Fgf2 may be modified as a result of
interactions with the extracellular matrix, a clear effect on
vesicle size was observed at all the concentrations tested.
Whereas CP cells in Matrigel are not induced to proliferate
in response to Fgf2, CP cells grown as monolayers, either
on laminin or collagen, significantly increase their prolif-
erative activity in the presence of low/medium Fgf2 con-
centrations. This different proliferative response may be
largely due to the differences in culture architecture in the
two models. CPe morphology is different in these two cul-
ture conditions, with cells being initially rounded and
then tightly packed to form a simple polarized epithelium
in Matrigel, and well-spread and flat in monolayers. An
environment-dependent proliferative effect of Fgf2 on
CPe cells is also consistent with previous work showing
that these cells behave differently when plated on differ-
ent matrices [39]. These authors tested growth factors
present in trace amounts in Matrigel, Tgfβ1, Tgfβ2 and
Pdgf, for their ability to increase penetration of CPe into
matrices, and suggested that Tgfβ2, but not Tgfβ1 and
Pdgf, can increase migration depending on matrix compo-
sition. A role of the environment in Fgf2-induced prolifer-
ative response is also consistent with in vivo studies
reporting increased proliferation in Fgf2-treated CPe in
pathological conditions, such as in a Parkinson's disease
model [23], but no obvious size changes in the CPe of
normal animals that developed Fgf2-induced hydroceph-
alus [23].
Fgf2 increases CPe cell aggregation rather than secretion
It has been previously shown that growth of CPe vesicles
depends on fluid secretion within the lumen [30]. Analy-
sis of vesicle growth rate has shown that Fgf2-induced
increase in vesicle size is not due to increased secretion
into the lumen. The slopes of the growth curves of vesicles
exposed to different Fgf2 concentrations are very similar,
and no increase in the rate of recovery of vesicles collapsed
using secretion inhibitors is induced by Fgf2 treatment. In
addition, if Fgf2 treatment is started at 6 days, once the
vesicles have already formed, no increase in vesicle size is
observed in treated cultures 4 days later. Transmission
electron microscopy analysis of Fgf2-treated vesicles (not
shown) is also consistent with lack of significant Fgf2
effects on secretion, as no obvious reduction in electron
density, which is thought to decrease in CPe with very
high secretory activity, is observed in these vesicles. Our
results in vitro are consistent with work suggesting that the
occurrence of hydrocephalus observed in response to Fgf2
treatment in vivo is not caused by a direct effect of Fgf2 on
CPe secretion, but could be due, at least in part, to a
decrease in CSF absorption caused by impaired function
of the arachnoid villi, the main structure involved in this
process [23].
Fgf2-induced vesicle growth is due to increased CPe cell
recruitment into the aggregates that form vesicles, as indi-
cated by a reduced number of aggregates and increase in
aggregate size in the presence of Fgf2. The mechanisms
underlying increased cell recruitment leading to forma-
tion of larger aggregates have yet to be fully elucidated,
but the present results suggest an increase in cell-cell adhe-
sion rather than in cell motility. Fgf2-treated aggregates
appear more compact than controls. Time-lapse micros-
copy analysis has not indicated any obvious increase in
cell motility in the presence of Fgf2 and, as discussed ear-
lier, proliferation does not appear to contribute to
increased aggregate size. E-cadherin could be a candidate
mediator of the effect of Fgf in the CPe, as it is expressed
in adult CP and Fgf treatment can upregulate E-cadherin
expression in pancreatic cancer cell lines [40-42]. A thor-
ough adhesion molecule profile of the CPe is required to
identify putative Fgf targets leading to increased cell aggre-
gation.
The fact that Fgf2 is expressed early during choroid plexus
development and appears to affect CPe cell-cell interac-
tion, rather than cell proliferation, is consistent with a role
of Fgf2 in maintaining the integrity of this epithelium as
recently suggested for endothelial cells of the blood brain
barrier [36].Cerebrospinal Fluid Research 2008, 5:20 http://www.cerebrospinalfluidresearch.com/content/5/1/20
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Fgf2 modulates expression of transcription factors 
associated with CPe homeostasis
The effect of Fgf2 on E2f5 and Foxj1 is of particular inter-
est, given the putative roles of these transcription factors
in the CPe. Knockouts of E2f5, a member of a family
(E2f1–E2f6) of transcriptional regulators and FoxJ1, a
member of the forkhead-box (Fox)/winged helix gene
family, have been associated with defective choroid
plexus function resulting in hydrocephalus [4-6]. Foxj1 is
associated with ciliogenesis and maturation of CPe
[4,9,43], and Fgf2-induced down-regulation of Foxj1 has
been reported in other cell types [12]. In addition, defects
in cilia formation have been recently reported in Fgf10
null mutants, supporting the view that Fgf signalling may
play a role in ciliogenesis [44]. E2f5 is a general cell cycle
regulator, but in the CPe seems associated with CPe func-
tion rather than proliferation [5,7]. Since E2f5 intracellu-
lar localization changes with CPe maturation, and the
FgfRs are differentially regulated during its development
[7,26], it is conceivable that Fgf signalling may play a role
in modulating translocation of this protein from the
nucleus to the cytoplasm in the developing CPe.
The dose-dependent effects of Fgf2 on proliferation
(induced at low/medium concentrations), and gene
expression (induced at high concentrations) in the CPe
cell line are akin to those observed in other cell types, such
as fibroblasts and cranial neural crest cells, where at lower
concentrations Fgf2 stimulates proliferation, whereas at
higher concentrations it appears to support survival and
differentiation [37,45].
Conclusion
Altogether, this study suggests that whereas Fgf2 does not
have a significant direct effect on CSF secretion, it is an
endogenous regulator of the Fgf signalling pathway in the
developing choroid plexus, given its conserved expression
in rodents and humans. Furthermore, Fgf2 is likely to play
a role in maintaining CPe integrity and function, as sug-
gested by the increase in CP cell aggregation and modula-
tion of gene expression observed in vitro. In order to better
understand the role of Fgf2 on cell-cell interaction it will
be important to identify which cell-cell adhesion mole-
cules might be modulated by Fgf2 in the CPe either at the
mRNA or protein level and other Fgf ligands that may be
crucial for Fgf signalling in the CPe.
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